Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Corbus pharmaceuticals - You Need To See This

Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Yuval Cohen outlined the company’s near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem. Cohen said the Norwood, Massachusetts-based dru

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human p

Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability and progression-free survival data for the company’s highlighted cervical and head and neck canc

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The 3 Best Cannabis Stocks to Buy for 2026

These three cannabis stocks mix regulatory optionality, steady operators, and biotech risk as investors position for 2026 reform tailwinds.

2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?

After more than doubling in the past year, is this clinical-stage biotech stock still a buy?

Up Over 700% YTD, Here's How Much Higher Analysts Think This Biotech Stock Can Rise

As the biotech industry rebounds from recent challenges, a favorable regulatory environment and groundbreaking scientific advancements are creating investment opportunities, particularly in companies with robust clinical pipelines and promising early-stage data.

inkl

Read news from The Economist, FT, and more,
with one subscription

Corbus Pharmaceuticals: Q1 Earnings Insights

Corbus Pharmaceuticals: Q1 Earnings Insights

Corbus Pharmaceuticals (NASDAQ:CRBP) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

5 Cannabis Stocks Wall Street Analysts Rate Buy: No, Tilray Is Not Among Them

5 Cannabis Stocks Wall Street Analysts Rate Buy: No, Tilray Is Not Among Them

The cannabis industry blossomed during the pandemic, some say unexpect

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

Corbus Pharmaceuticals: Q4 Earnings Insights

Corbus Pharmaceuticals: Q4 Earnings Insights

Corbus Pharmaceuticals (NASDAQ:CRBP) reported its Q4 earnings results on Tuesday, March 8, 2022 at 08:05 AM. Here's what investors need to know about the announcement.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

RBC Capital Markets

Viking Therapeutics

Green Thumb Industries

Corbus Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Cervical Cancer

Places

417,264 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play